Global Neuropathic Pain Treatment Market to Reach US$8.42 Billion by 2030 as Non-Opioid Innovation Accelerates Growth: Epignosis Insights
Epignosis Insights, a market research and brand intelligence consultancy, has released its latest report on the Global Neuropathic Pain Treatment Market. The study estimates that the market was valued at US$6.04 billion in 2024 and will reach US$8.42 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.7% between 2024 and 2030.
Rather than focusing only on revenue, the report examines the market through a set of patient and commercial indicators, including the global patient funnel, treated patient numbers, revenue per treated patient, generic versus branded share and the clinical pipeline. Companies are benchmarked using the Epignosis Insights Competitive Assessment Framework (EICAF).
Key Highlights of the Report
- Market value is forecast to increase from US$6.04 billion in 2024 to US$8.42 billion by 2030.
- Annual growth is expected to accelerate from 4.3% in 2025 to 7.1% by 2030.
- An estimated 72 million patients received prescription therapy in 2025, rising to 85.6 million by 2030.
- Only around 5% of the estimated 450 million adults with neuropathic pain symptoms achieve meaningful pain relief.
- Global revenue per treated patient is forecast to rise from US$87.5 in 2025 to US$98.4 by 2030.
- Novel non-opioid agents are expected to grow from about 1% of market value in 2025 to 13% by 2030.
A Market Entering a New Growth Phase
A key finding of the report is that the neuropathic pain treatment market is speeding up after years of slow growth. Annual growth was only 2.0% in 2021, held back by generic erosion of major branded medicines. Epignosis Insights estimates growth reached 4.3% in 2025 and expects it to rise to 7.1% by 2030.
"Neuropathic pain has been dominated for two decades by medicines originally developed for epilepsy and depression," said a spokesperson for Epignosis Insights. "What we are seeing now is the first real innovation cycle in years. New non-opioid mechanisms are moving through late-stage development, and that is lifting both growth and the value of each treated patient."
A Large and Underserved Patient Population
The report highlights the scale of unmet need. Epignosis Insights estimates that about 450 million adults worldwide experienced neuropathic pain symptoms in 2025. Of these, around 135 million were clinically diagnosed, 72 million received prescription therapy and only about 24 million achieved meaningful relief, defined as at least a 30% reduction in pain.
The gap between treatment and relief is the most significant. Many patients receive limited benefit from current first-line therapies or stop treatment because of side effects such as dizziness and sedation, creating a strong case for new options.
Regional Insights
North America is the largest market, valued at US$2.57 billion in 2024 and projected to reach US$3.52 billion by 2030. It accounts for 42.4% of 2025 global value. Asia Pacific is the fastest growing major region at a 6.9% CAGR and overtook Europe by value in 2023. It is expected to reach US$2.55 billion by 2030, increasing its share to 30.2%. Europe is forecast to grow from US$1.65 billion to US$2.20 billion.
The report also finds that North America generates about US$282 per treated patient each year, compared with US$142 in Europe and US$41 in Asia Pacific, highlighting very different commercial models across regions.
Generic Dominance and the Shift to Innovation
Generic medicines account for about 88% of prescriptions but only 52% of market value. Gabapentinoids remain the largest drug class at 38% of 2025 value, followed by SNRIs and TCAs at 22%. By 2030, the share of gabapentinoids is expected to fall to 31%, while novel non-opioid agents rise to 13%.
Pipeline Activity
Epignosis Insights tracks 58 clinical-stage neuropathic pain assets, including 7 in Phase 3 and 1 filed or registered. Sodium-channel inhibitors form the largest group with 20 assets, reflecting strong industry interest in non-opioid mechanisms.
Indication Insights
Painful diabetic peripheral neuropathy is the largest indication, representing 36% of 2025 market value, followed by radiculopathy and sciatica at 18% and postherpetic neuralgia at 12%. Chemotherapy-induced neuropathy is identified as a key growth opportunity.
Competitive Landscape
The report profiles companies including Viatris, Eli Lilly and Company, Grünenthal, Daiichi Sankyo, Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Keenova Therapeutics, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Zydus Lifesciences, Lupin, Dr. Reddy's Laboratories, Cipla and Aurobindo Pharma. Under EICAF, portfolio efficacy and differentiation carries the highest weighting at 15%, followed by clinical pipeline strength at 14%.
Report Coverage
- By Drug Class: Gabapentinoids, SNRIs and TCAs, Topical Agents, Opioids and Tramadol, Sodium-Channel Anticonvulsants, Novel Non-Opioid Agents, Others
- By Indication: Diabetic Peripheral Neuropathy, Radiculopathy, Postherpetic Neuralgia, Chemotherapy-Induced Neuropathy, Post-Surgical, Central Pain, Trigeminal Neuralgia, Others
- By Route and Channel: Oral, Topical, Injectable; Hospital, Retail and Online Pharmacies
- By Region: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
About Epignosis Insights
Epignosis Insights is a Pune-based market research and brand intelligence consultancy delivering data-driven insights to support smarter business decisions. The firm provides B2B market reports, brand tracking studies, pricing trackers, product and innovation research, and customer experience research across healthcare, pharmaceuticals, chemicals, consumer goods, energy and technology.